Literature DB >> 16871562

Tenofovir disoproxil fumarate: role in hepatitis B treatment.

Stephen N Wong, Anna S F Lok.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16871562     DOI： 10.1002/hep.21307

Source DB:  PubMed          Journal:  Hepatology        ISSN： 0270-9139            Impact factor:   17.425


× No keyword cloud information.
  6 in total

1.  In vitro activity of 2,4-diamino-6-[2-(phosphonomethoxy)ethoxy]-pyrimidine against multidrug-resistant hepatitis B virus mutants.

Authors:  M N Brunelle; J Lucifora; J Neyts; S Villet; A Holy; C Trepo; F Zoulim
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

2.  Tenofovir versus entecavir in treatment of chronic hepatitis B virus with severe acute exacerbation.

Authors:  Chao-Hung Hung; Tsung-Hui Hu; Sheng-Nan Lu; Chuan-Mo Lee; Chih-Hung Chen; Kwong-Ming Kee; Jing-Houng Wang; Ming-Chao Tsai; Yuan-Hung Kuo; Kuo-Chin Chang; Yi-Chun Chiu; Chien-Hung Chen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-16       Impact factor: 5.191

Review 3.  Tenofovir disoproxil fumarate: in chronic hepatitis B.

Authors:  Caroline M Perry; Dene Simpson
Journal:  Drugs       Date:  2009-11-12       Impact factor: 9.546

4.  Low-dose tenofovir is more potent than adefovir and is effective in controlling HBV viremia in chronic HBeAg-negative hepatitis B.

Authors:  Paolo Del Poggio; Maurizio Zaccanelli; Maria Oggionni; Silvia Colombo; Carlo Jamoletti; Vesna Puhalo
Journal:  World J Gastroenterol       Date:  2007-08-14       Impact factor: 5.742

Review 5.  Antiviral drugs for viruses other than human immunodeficiency virus.

Authors:  Raymund R Razonable
Journal:  Mayo Clin Proc       Date:  2011-10       Impact factor: 7.616

6.  Tenofovir and its potential in the treatment of hepatitis B virus.

Authors:  Laura Reynaud; Maria Aurora Carleo; Maria Talamo; Guglielmo Borgia
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.